abstract of the disclosure [0095] the present invention relates to methods for preventing or treating human immunodeficiency virus (hiv) infection, inflammatory conditions, and graft-versus-host-disease (gvhd) in a subject. therapeutic compositions of the present invention comprising leukocidin and (luke) and / or proteins or polypeptides. the invention further relates to methods of treating staphylococcus aureus infection by administering a composition comprising a ccr5 antagonist or any molecule that blocks luke / d interaction with ccr5 + cells in an effective amount to treat the s. aureus infection in the subject. "Leukotoxin e / d as a new anti-inflammatory and microbicidal agent". The present invention relates to methods for preventing or treating human immunodeficiency virus (hiv) infection, inflammatory conditions, and graft versus host disease (gvhd) in a subject. Therapeutic compositions of the present invention comprise leukocidine and (luke) and / or d proteins or polypeptides. The invention further relates to methods for treating staphylococus aureus infection by administering a composition comprising a ccr5 antagonist or any molecule that blocks luke / d interaction with ccr5 + cells in an amount effective to treat sC infection. aureus in the subject.abstract of the disclosure [0095] the present invention relates to methods for preventing or treating human immunodeficiency virus (hiv) infection, inflammatory conditions, and graft-versus-host-disease (gvhd) in a subject. therapeutic compositions of the present invention comprise leukocidin e (luke) and/or d proteins or polypeptides. the invention further relates to methods of treating staphylococcus aureus infection by administering a composition comprising a ccr5 antagonist or any molecule that blocks luke/d interaction with ccr5+ cells in an amount effective to treat the s. aureus infection in the subject. tradução do resumo resumo patente de invenção: "leucotoxina e/d como um novo agente anti-inflama
